Evidence map›Paper›PMID 42904000›Full record

ReviewhLife2024

Phenazines: Natural products for microbial growth control.

Cátia A Sousa, Marta Ribeiro, Francisca Vale, Manuel Simões

Abstract readReview
In one paragraph

Review in hLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cátia A SousaISEP/P.PORTO, School of Engineering, Polytechnic of Porto, Porto, Portugal.
Marta RibeiroLEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Porto, Portugal.
Francisca ValeLEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Porto, Portugal.
Manuel SimõesLEPABE - Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Porto, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unprecedented problem of antibiotic resistance has become a major challenge for public health, which has contributed to an increase in infections caused by such bacteria. These microbial infections, typically biofilm-related, are also coupled to an increase in human mortality and morbidity. However, the demand for new antimicrobial agents has increased along with the evolution of microbial resistance mechanisms. Natural products produced by bacteria, such as phenazines, have been recognized as an important source for the development of new antimicrobial agents, through the exploitation of their capacity to increase oxidative stress in other organisms. Phenazines are a large group of nitrogen-containing heterocyclic compounds and are essential for several cellular processes including iron acquisition, signaling events, enzymatic processes, and biofilm formation. Phenazine-inspired antibiotics (i.e., 2-bromo-1-hydroxyphenazine, 2,4-dibromo-1-hydroxyphenazine, bromophenazine-21, phenazine-13, and phenazine-14) are very active against a wide range of gram-positive and gram-negative bacteria, including those associated with severe infections. In this study, mechanisms of phenazine-inspired antibiotics in the cellular processes of planktonic and sessile bacteria are reviewed. Moreover, the application of phenazine-inspired antibiotics for the eradication of multidrug-resistant planktonic and biofilm bacterial infections is also reviewed.

Indexed as

antimicrobial agentsbiofilmsmultidrug-resistantnatural productsphenazines

Identifiers

PMID42904000
PMCPMC13681589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.